In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Janssen Biotech gets ex-South Korean rights to Yuhan's lazertinib for NSCLC

Executive Summary

In a deal potentially worth up to $1.25bn, South Korean pharmaco Yuhan Corp. licensed Janssen Biotech Inc. exclusive worldwide rights (excluding South Korea where Yuhan retains rights) to develop, manufacture, and commercialize its lazertinib for non-small cell lung cancer (NSCLC).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies